Accuray Incorporated

NasdaqGS:ARAY Stock Report

Market Cap: US$185.0m

Accuray Valuation

Is ARAY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ARAY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ARAY's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ARAY's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ARAY?

Key metric: As ARAY is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ARAY. This is calculated by dividing ARAY's market cap by their current revenue.
What is ARAY's PS Ratio?
PS Ratio0.4x
SalesUS$444.20m
Market CapUS$185.04m

Price to Sales Ratio vs Peers

How does ARAY's PS Ratio compare to its peers?

The above table shows the PS ratio for ARAY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.5x
NVRO Nevro
0.4x2.5%US$158.9m
ZJYL Jin Medical International
7.9xn/aUS$158.1m
STXS Stereotaxis
6.8x49.7%US$173.7m
PDEX Pro-Dex
2.7x5.8%US$147.4m
ARAY Accuray
0.4x5.5%US$185.0m

Price-To-Sales vs Peers: ARAY is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (4.5x).

Price to Sales Ratio vs Industry

How does ARAY's PS Ratio compare vs other companies in the US Medical Equipment Industry?

52 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.3.2x8.2%
ARAY Accuray
 0.4x5.5%US$185.04m
INGN Inogen
0.7x4.2%US$226.04m
NVRO Nevro
0.4x2.5%US$158.88m
ARAY 0.4xIndustry Avg. 3.2xNo. of Companies52PS02.85.68.411.214+
52 CompaniesEstimated GrowthMarket Cap
Industry Avg.3.2x17.1%
ARAY Accuray
 0.4x111.7%US$185.04m
No more companies

Price-To-Sales vs Industry: ARAY is good value based on its Price-To-Sales Ratio (0.4x) compared to the US Medical Equipment industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is ARAY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ARAY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ratio0.5x

Price-To-Sales vs Fair Ratio: ARAY is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (0.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ARAY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.83
US$6.13
+234.7%
8.9%US$7.00US$5.50n/a4
Nov ’25US$1.75
US$6.13
+250.0%
8.9%US$7.00US$5.50n/a4
Oct ’25US$1.72
US$6.13
+256.1%
8.9%US$7.00US$5.50n/a4
Sep ’25US$2.18
US$6.13
+181.0%
8.9%US$7.00US$5.50n/a4
Aug ’25US$1.69
US$6.00
+255.0%
11.8%US$7.00US$5.00n/a4
Jul ’25US$1.76
US$6.00
+240.9%
11.8%US$7.00US$5.00n/a4
Jun ’25US$1.77
US$6.00
+239.0%
11.8%US$7.00US$5.00n/a4
May ’25US$2.17
US$8.75
+303.2%
30.6%US$13.00US$6.00n/a4
Apr ’25US$2.41
US$8.75
+263.1%
30.6%US$13.00US$6.00n/a4
Mar ’25US$2.61
US$8.75
+235.2%
30.6%US$13.00US$6.00n/a4
Feb ’25US$2.56
US$8.67
+238.5%
35.7%US$13.00US$6.00n/a3
Jan ’25US$2.83
US$8.50
+200.4%
31.7%US$13.00US$6.00n/a4
Dec ’24US$2.54
US$8.50
+234.6%
31.7%US$13.00US$6.00n/a4
Nov ’24US$2.57
US$8.30
+223.0%
29.4%US$13.00US$6.00US$1.755
Oct ’24US$2.72
US$8.30
+205.1%
29.4%US$13.00US$6.00US$1.725
Sep ’24US$2.92
US$8.30
+184.2%
29.4%US$13.00US$6.00US$2.185
Aug ’24US$4.21
US$8.30
+97.1%
29.4%US$13.00US$6.00US$1.695
Jul ’24US$3.87
US$8.30
+114.5%
29.4%US$13.00US$6.00US$1.765
Jun ’24US$3.58
US$8.30
+131.8%
29.4%US$13.00US$6.00US$1.775
May ’24US$3.46
US$8.30
+139.9%
29.4%US$13.00US$6.00US$2.175
Apr ’24US$2.97
US$8.17
+175.0%
27.5%US$13.00US$6.00US$2.416
Mar ’24US$2.87
US$8.17
+184.6%
27.5%US$13.00US$6.00US$2.616
Feb ’24US$2.45
US$8.17
+233.3%
27.5%US$13.00US$6.00US$2.566
Jan ’24US$2.09
US$8.17
+290.7%
27.5%US$13.00US$6.00US$2.836
Dec ’23US$2.10
US$8.17
+288.9%
27.5%US$13.00US$6.00US$2.546
Nov ’23US$2.00
US$8.33
+316.7%
25.4%US$13.00US$7.00US$2.576

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Centene

US$29.2b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$59.10

7D

1.8%

1Y

-20.4%

Elevance Health

US$91.4b

Operates as a health benefits company in the United States.

ELV

US$397.48

7D

-3.3%

1Y

-17.2%

CVS Health

US$70.2b

Provides health solutions in the United States.

CVS

US$56.83

7D

4.7%

1Y

-17.8%